Turn Therapeutics (NASDAQ:TTRX) Director Arthur Golden Purchases 9,868 Shares

Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden purchased 9,868 shares of the firm's stock in a transaction that occurred on Monday, November 24th. The stock was acquired at an average price of $3.44 per share, with a total value of $33,945.92. Following the completion of the purchase, the director owned 60,602 shares in the company, valued at $208,470.88. This represents a 19.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Turn Therapeutics Stock Performance

NASDAQ:TTRX opened at $3.30 on Wednesday. Turn Therapeutics Inc. has a one year low of $2.57 and a one year high of $26.50.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Turn Therapeutics Company Profile

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.

Further Reading

• Five stocks we like better than Turn Therapeutics
• 3 Fintech Stocks With Good 2021 Prospects
• History Says These are 3 Stocks to Buy for December
• Asset Allocation Strategies in Volatile Markets
• Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
• What Is WallStreetBets and What Stocks Are They Targeting?
• From Science Project to Solvent: WeRide’s 761% Revenue Surge

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].